John Matelski
University Health Network
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John Matelski.
International Journal of Drug Policy | 2017
Kate Mason; Zoë Dodd; Mary Guyton; Paula Tookey; Bernadette Lettner; John Matelski; Sanjeev Sockalingam; Jason Altenberg; Jeff Powis
BACKGROUND Direct acting antiviral (DAA) treatments for Hepatitis C (HCV) are now widely available with sustained virologic response (SVR) rates of >90%. A major predictor of response to DAAs is adherence, yet few real-world studies evaluating adherence among marginalized people who use drugs and/or alcohol exist. This study evaluates patterns and factors associated with non-adherence among marginalized people with a history of drug use who were receiving care through a primary care, community-based HCV treatment program where opiate substitution is not offered on-site. METHODS Prospective evaluation of chronic HCV patients initiating DAA treatment. Self-report medication adherence questionnaires were completed weekly. Pre/post treatment questionnaires examined socio-demographics, program engagement and substance use. Missing adherence data was counted as a missed dose. RESULTS Of the 74 participants, who initiated treatment, 76% were male, the average age was 54 years, 69% reported income from disability benefits, 30% did not have stable housing and only 24% received opiate substitution therapy. Substance use was common in the month prior to treatment initiation with, 11% reported injection drug use, 30% reported non-injection drug use and 18% moderate to heavy alcohol use. The majority (85%) were treatment naïve, with 76% receiving sofosbuvir/ledipasvir (8-24 weeks) and 22% Sofosbuvir/Ribarvin (12-24 weeks). The intention to treat proportion with SVR12 was 87% (60/69). In a modified ITT analysis (excluding those with undetectable RNA at end of treatment), 91% (60/66) achieved SVR12. Overall, 89% of treatment weeks had no missed doses. 41% of participants had at least one missed dose. In multivariate analysis the only factor independently associated with weeks with missed doses was moderate to heavy alcohol use (p=0.05). CONCLUSION This study demonstrates that strong adherence and SVR with DAAs is achievable, with appropriate supports, even in the context of substance use, and complex health/social issues.
BMJ | 2017
Jessica Liu; Chaim M. Bell; John Matelski; Peter Cram
Objective To estimate financial payments from industry to US journal editors. Design Retrospective observational study. Setting 52 influential (high impact factor for their specialty) US medical journals from 26 specialties and US Open Payments database, 2014. Participants 713 editors at the associate level and above identified from each journal’s online masthead. Main outcome measures All general payments (eg, personal income) and research related payments from pharmaceutical and medical device manufacturers to eligible physicians in 2014. Percentages of editors receiving payments and the magnitude of such payments were compared across journals and by specialty. Journal websites were also reviewed to determine if conflict of interest policies for editors were readily accessible. Results Of 713 eligible editors, 361 (50.6%) received some (>
Academic Medicine | 2017
Asim Alam; John Matelski; Hanna R. Goldberg; Jessica Liu; Jason Klemensberg; Chaim M. Bell
0) general payments in 2014, and 139 (19.5%) received research payments. The median general payment was
Medicine | 2015
Jessica Liu; Asim Alam; Hanna R. Goldberg; John Matelski; Chaim M. Bell
11 (£8; €9) (interquartile range
Circulation-cardiovascular Quality and Outcomes | 2016
Jessica Liu; John Matelski; Peter Cram; David R. Urbach; Chaim M. Bell
0-2923) and the median research payment was
Journal of Orthopaedic Trauma | 2016
Christine Soong; Peter Cram; Ksenia Chezar; Faiqa Tajammal; Kathleen Exconde; John Matelski; Samir K. Sinha; Howard Abrams; Christopher Fan-Lun; Christina Fabbruzzo-Cota; David Backstein; Chaim M. Bell
0 (
Clinical Orthopaedics and Related Research | 2018
Joyce C. Zhang; John Matelski; Rajiv Gandhi; Timothy Jackson; David R. Urbach; Peter Cram
0-0). The mean general payment was
JAMA Internal Medicine | 2018
Safiyyah Mahomed; Jaime Rosenthal; John Matelski; Peter Cram
28 136 (SD
The Joint Commission Journal on Quality and Patient Safety | 2018
Thurarshen Jeyalingam; John Matelski; Asim Alam; Jessica Liu; Hanna R. Goldberg; Jason Klemensberg; Chaim M. Bell
415 045), and the mean research payment was
Arthritis & Rheumatism | 2018
Peter Cram; Bruce E. Landon; John Matelski; Vicki Ling; Therese A. Stukel; J. Michael Paterson; Rajiv Gandhi; Gillian Hawker; Bheeshma Ravi
37 963 (SD